{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:15:54Z","timestamp":1778822154425,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>We have studied the possible effects of an intensive lifestyle change program on plasma fibrinogen levels, in patients with no cardiovascular disease, with elevated levels of fibrinogen, normal cholesterol levels, and a moderate estimated risk of coronary heart disease (CHD) and we have also analysed whether the effect on fibrinogen is independent of the effect on lipids.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>This clinical trial was controlled, unblinded and randomized, with parallel groups, done in 13 Basic Health Areas (BHA) in l'Hospitalet de Llobregat (Barcelona) and Barcelona city. The study included 436 patients, aged between 35 and 75 years, with no cardiovascular disease, elevated levels of fibrinogen (&gt; 300 mg\/dl), cholesterol &lt; 250 mg\/dl, 218 of whom received a more intensive intervention consisting of advice on lifestyle and treatment. The follow-up frequency of the intervention group was every 2 months. The other 218 patients followed their standard care in the BHAs. Fibrinogen, plasma cholesterol and other clinical biochemistry parameters were assessed.<\/jats:p>\n            <jats:p>The evaluation of the baseline characteristics of the patients showed that both groups were homogenous. Obesity and hypertension were the most prevalent risk factors. After 24 months of the study, statistically significant changes were seen between the adjusted means of the two groups, for the following parameters: fibrinogen, plasma cholesterol, systolic and diastolic blood pressure and body mass index.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Intensive intervention to achieve lifestyle changes has shown to be effective in reducing some of the estimated CHD factors. However, the effect of intensive intervention on plasma fibrinogen levels did not correlate with the variations in cholesterol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial Registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01089530\" ext-link-type=\"uri\">NCT01089530<\/jats:ext-link>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-0500-5-126","type":"journal-article","created":{"date-parts":[[2012,3,2]],"date-time":"2012-03-02T22:26:16Z","timestamp":1330727176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Randomised clinical trial of an intensive intervention in the primary care setting of patients with high plasma fibrinogen in the primary prevention of cardiovascular disease"],"prefix":"10.1186","volume":"5","author":[{"given":"Juan","family":"Jos\u00e9 Rodr\u00edguez Crist\u00f3bal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Alonso-Villaverde Grote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Trav\u00e9 Mercad\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"M\u00aa P\u00e9rez Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Pe\u00f1a Sendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mu\u00f1oz Lloret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Fern\u00e1ndez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domingo","family":"Bleda Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The EFAP group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,1]]},"reference":[{"key":"1439_CR1","first-page":"102","volume":"20","author":"JJ Rodr\u00edguez Crist\u00f3bal","year":"2008","unstructured":"Rodr\u00edguez Crist\u00f3bal JJ, Villaverde Grote CA, Flor Serra F, Trav\u00e9 Mercad\u00e9 P, P\u00e9rez Santos JM, Pe\u00f1a Sendra E, en representaci\u00f3n del grupo EFAP: Ensayo cl\u00ednico de intervenci\u00f3n en pacientes con hiperfibrinogenemia en prevenci\u00f3n primaria de enfermedad cardiovascular en el \u00e1mbito de la atenci\u00f3n primaria de salud. Clin Invet Arterioscl. 2008, 20: 102-9.","journal-title":"Clin Invet Arterioscl"},{"key":"1439_CR2","doi-asserted-by":"publisher","first-page":"956","DOI":"10.7326\/0003-4819-118-12-199306150-00008","volume":"118","author":"E Ernst","year":"1993","unstructured":"Ernst E, Resch KL: Fibrinogen as cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993, 118: 956-63.","journal-title":"Ann Intern Med"},{"key":"1439_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s11745-005-1488-8","volume":"40","author":"WB Kannel","year":"2005","unstructured":"Kannel WB: Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipid. 2005, 40: 1215-20. 10.1007\/s11745-005-1488-8.","journal-title":"Lipid"},{"key":"1439_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/1047-2797(94)90071-X","volume":"4","author":"A Dotevall","year":"1994","unstructured":"Dotevall A, Johansson S, Wilhelmsen L: Associaton between fibrinogen and other risk factor for cardiovascular disease in men and women. Results from the Goteborg MONICA survey 1985. Ann Epidemiol. 1994, 4: 369-74. 10.1016\/1047-2797(94)90071-X.","journal-title":"Ann Epidemiol"},{"issue":"Suppl A","key":"1439_CR5","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1093\/eurheartj\/16.suppl_A.47","volume":"16","author":"E Ernst","year":"1995","unstructured":"Ernst E, Resch KL: Therapeutic interventions to lower plasma fibrinogen concentration. Eur Heart J. 1995, 16 (Suppl A): S47-53.","journal-title":"Eur Heart J"},{"key":"1439_CR6","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jama.279.18.1477","volume":"279","author":"J Danesh","year":"1998","unstructured":"Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998, 279: 1477-82. 10.1001\/jama.279.18.1477.","journal-title":"JAMA"},{"key":"1439_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1136\/jech.52.11.707","volume":"52","author":"R Masi\u00e1","year":"1998","unstructured":"Masi\u00e1 R, Pena A, Marrugat J, Sala J, Vila J, Pavesi M, Covas M, Aub\u00f3 C, Elosua R: High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. REGICOR Investigators. J Epidemiol Community Health. 1998, 52: 707-15. 10.1136\/jech.52.11.707.","journal-title":"J Epidemiol Community Health"},{"key":"1439_CR8","first-page":"495","volume":"14","author":"B Gil","year":"1997","unstructured":"Gil B, Avil\u00e9s J, Maldonado A, Fern\u00e1ndez M: Factores de riesgo en ancianos. Estudio de 143 cientes. An Med Intern (Madrid). 1997, 14: 495-9.","journal-title":"An Med Intern (Madrid)"},{"key":"1439_CR9","first-page":"78","volume-title":"Relationship between cholesterol and fibrinogen in primary-care areas. 15 the Wonca World Conference","author":"JJ Rodr\u00edguez","year":"1998","unstructured":"Rodr\u00edguez JJ, Villaverde CA, Torell\u00f3 L, Trocho C, Tibau N, Villaverde AA: Relationship between cholesterol and fibrinogen in primary-care areas. 15 the Wonca World Conference. 1998, 78-"},{"key":"1439_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0014-2565(04)71500-3","volume":"204","author":"JJ Rodr\u00edguez Crist\u00f3bal","year":"2004","unstructured":"Rodr\u00edguez Crist\u00f3bal JJ, Villaverde Grote CA, Tibau Llard\u00e9n N, Juan Babot O, Andrades Corrales A, Pe\u00f1a Sendra E: Relationship between cholesterol and fibrinogen in two populations of different geographical location of Catalonia. Rev Clin Esp. 2004, 204: 405-9. 10.1157\/13064313.","journal-title":"Rev Clin Esp"},{"key":"1439_CR11","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1161\/01.ATV.21.6.1065","volume":"21","author":"K Yano","year":"2001","unstructured":"Yano K, Grove J, Chen R, Rodr\u00edguez BL, Curb JD, Tracy RP: Plasma fibrinogen as a predictor of total and cause-specific mortality in elderly Japanese-American men. Arterio Throm Vascul Biol. 2001, 21: 1065-70. 10.1161\/01.ATV.21.6.1065.","journal-title":"Arterio Throm Vascul Biol"},{"key":"1439_CR12","first-page":"262","volume":"5-6","author":"D Wood","year":"1998","unstructured":"Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Py\u00f6r\u00e4l\u00e4 K: Prevention of coronary heart disease in clinical practice. Summary of recommendations the second joint task force of European and other societies on coronary prevention. Blood Press. 1998, 5-6: 262-9.","journal-title":"Blood Press"},{"issue":"Suppl 3","key":"1439_CR13","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.2165\/00003495-199700543-00006","volume":"54","author":"WB Kannel","year":"1997","unstructured":"Kannel WB: Influence of fibrinogen on cardiovascular disease. Drugs. 1997, 54 (Suppl 3): S32-40.","journal-title":"Drugs"},{"key":"1439_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1157\/13072792","volume":"35","author":"JJ Rodr\u00edguez Crist\u00f3bal","year":"2005","unstructured":"Rodr\u00edguez Crist\u00f3bal JJ, Benavides M\u00e1rquez F, Villaverde Grote C, Pe\u00f1a Sendra E, Flor Serra F, Trav\u00e9 Mercad\u00e9 P, EFAP Group: Randomised clinical trial of an intensive intervention into life-styles of patients with hyperfibrinogenaemia in primary prevention of cardiovascular pathology in primary health care. Aten Primaria. 2005, 35: 260-4. 10.1157\/13072792.","journal-title":"Aten Primaria"},{"key":"1439_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0025-7753(00)71632-0","volume":"115","author":"Sociedad Espa\u00f1ola para el Estudio de la Obesidad (SEEDO)","year":"2000","unstructured":"Sociedad Espa\u00f1ola para el Estudio de la Obesidad (SEEDO): Consenso SEEDO'2000 para la evaluaci\u00f3n del sobrepeso y la obesidad y el establecimiento de criterios de intervenci\u00f3n terap\u00e9utica. Med Clin (Barc). 2000, 115: 587-597.","journal-title":"Med Clin (Barc)"},{"issue":"Suppl 3","key":"1439_CR16","first-page":"15","volume":"39","author":"A Maiques","year":"2007","unstructured":"Maiques A, Villar F, Brotons C, Torcal J, Orozco-Beltran D, Navarro P, Lobos-Bejarano JM, Banegas B, Ortega S, Gil G, Solana S: Recomendaciones preventivas cardiovasculares en atenci\u00f3n primaria. Grupo de expertos del PAPPS. Aten Primaria. 2007, 39 (Suppl 3): 15-26.","journal-title":"Aten Primaria"},{"key":"1439_CR17","first-page":"177","volume-title":"Health Promotion and Disease Prevention in Clinical Practice","author":"S Woolf","year":"1996","unstructured":"Woolf S, Jonas S, Lawrence R: Health Promotion and Disease Prevention in Clinical Practice. 1996, Baltimore: Williams & Wilkins, 177-223."},{"key":"1439_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1157\/13074389","volume":"124","author":"MJ Medrano","year":"2005","unstructured":"Medrano MJ, Cerrato E, Boix R, Delgado-Rodr\u00edguez M: Factores de riesgo cardiovascular en la poblaci\u00f3n espa\u00f1ola: metaan\u00e1lisis de estudios transversales. Med Clin (Barc). 2005, 124: 606-12. 10.1157\/13074389.","journal-title":"Med Clin (Barc)"},{"key":"1439_CR19","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1056\/NEJMoa050156","volume":"353","author":"TA Wadden","year":"2005","unstructured":"Wadden TA, Berkowitz R, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ: Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005, 353: 2111-20. 10.1056\/NEJMoa050156.","journal-title":"N Engl J Med"},{"key":"1439_CR20","volume-title":"Intervenciones psicol\u00f3gicas para el sobrepeso o la obesidad (Revisi\u00f3n Cochrane)","author":"K Shaw","year":"2005","unstructured":"Shaw K, O'Rourke P, Del Mar C, Kenardy J: Intervenciones psicol\u00f3gicas para el sobrepeso o la obesidad (Revisi\u00f3n Cochrane). The Cochrane Library. 2005, [http:\/\/www.update-software.com]4"},{"key":"1439_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2105\/AJPH.91.2.265","volume":"91","author":"A Steptoe","year":"2001","unstructured":"Steptoe A, Kerry S, Rink E, Hilton S: The impact of behavioral counseling on stage of change in fat intake, physical activity, and cigarette smoking in adults at increased risk of coronary heart disease. Am J Public Health. 2001, 91: 265-9.","journal-title":"Am J Public Health"},{"key":"1439_CR22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0300-8932(07)75064-9","volume":"60","author":"S Sans","year":"2007","unstructured":"Sans S, Fitzgerald AP, Royo D, Conroy R, Gram I: Calibraci\u00f3n de la tabla SCORE de riesgo cardiovascular para Espa\u00f1a. Rev Esp Cardiol. 2007, 60: 476-85.","journal-title":"Rev Esp Cardiol"},{"key":"1439_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/jech.2005.038505","volume":"61","author":"J Marrugat","year":"2007","unstructured":"Marrugat J, Subirana I, Com\u00edn E, Cabezas C, Vila J, Elosua R, Nam BH, Ramos R, Sala J, Solanas P, Cord\u00f3n F, Gen\u00e9-Badia J, D'Agostino RB, VERIFICA Investigators: Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health. 2007, 61: 40-7. 10.1136\/jech.2005.038505.","journal-title":"J Epidemiol Community Health"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-5-126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T18:42:28Z","timestamp":1630521748000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/1756-0500-5-126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1439"],"URL":"https:\/\/doi.org\/10.1186\/1756-0500-5-126","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,1]]},"assertion":[{"value":"5 July 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"126"}}